Blog

Kite Pharma’s ASCO ads aim to prep docs on CAR-T ahead of FDA approval – FiercePharma


FiercePharma

Kite Pharma's ASCO ads aim to prep docs on CART ahead of FDA approval
FiercePharma
Kite Pharma is hoping to bring the first CART drug to the U.S. this year with its candidate KTE-C19. Kite began its rolling submission with the FDA in early December for an indication in relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma

2017-06-05 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.